|
Volumn 3, Issue 3, 2005, Pages 221-222
|
The ubiquitin-proteasome pathway: Limitations and opportunities
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CISPLATIN;
CYSTEMUSTINE;
CYTOKINE;
FREE RADICAL;
GLUCOCORTICOID;
IFOSFAMIDE;
IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;
MUSCLE PROTEIN;
PROTEASOME;
UBIQUITIN;
UBIQUITIN PROTEIN LIGASE E3;
ADENOCARCINOMA;
CACHEXIA;
CANCER CHEMOTHERAPY;
CANCER MORTALITY;
CANCER PATIENT;
CATABOLISM;
DISEASE MODEL;
DOWN REGULATION;
DRUG MECHANISM;
HUMAN;
MORBIDITY;
MUSCLE ATROPHY;
NONHUMAN;
PATHOPHYSIOLOGY;
PROTEIN DEGRADATION;
PROTEIN FUNCTION;
QUALITY OF LIFE;
REVIEW;
SIGNAL TRANSDUCTION;
UBIQUITINATION;
UPREGULATION;
BLOOD PROTEINS;
CYTOKINES;
GLUCOCORTICOIDS;
HUMANS;
MUSCLE PROTEINS;
MUSCULAR ATROPHY;
PROTEASOME ENDOPEPTIDASE COMPLEX;
SIGNAL TRANSDUCTION;
UBIQUITINS;
|
EID: 20744432494
PISSN: 15446794
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (6)
|
References (6)
|